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The atrioventricular heart valve leaflets and chordae tendineae are composed of diverse cell lineages and highly organized extracellular
matrices that share characteristics with cartilage and tendon cell types in the limb buds and somites. During embryonic chicken valvulogenesis,
aggrecan and sox9, characteristic of cartilage cells, are observed in the AV valve leaflets, in contrast to tendon-associated genes scleraxis and
tenascin, present in the chordae tendineae. In the limb buds and somites, cartilage cell lineage differentiation is regulated by BMP2, while FGF4
controls tendon cell fate. The ability of BMP2 and FGF4 to induce similar patterns of gene expression in heart valve precursor cells was examined.
In multiple assays of cells from prefused endocardial cushions, BMP2 is sufficient to activate Smad1/5/8 phosphorylation and induce sox9 and
aggrecan expression, while FGF4 treatment increases phosphorylated MAPK (dpERK) signaling and promotes expression of scleraxis and
tenascin. However, these treatments do not alter differentiated lineage gene expression in valve progenitors from fused cushions of older embryos.
Together, these studies define regulatory pathways of AV valve progenitor cell diversification into leaflets and chordae tendineae that share
inductive interactions and differentiation phenotypes with cartilage and tendon cell lineages.
© 2006 Elsevier Inc. All rights reserved.Keywords: Heart; Valve remodeling; Cell lineage; Chick; BMP; FGFIntroduction
The tricuspid and mitral atrioventricular (AV) heart valves
are complex structures required for unidirectional blood flow,
and malformations of these valves can lead to congenital heart
disease (Armstrong and Bischoff, 2004). Human, mouse, and
chicken AV valves are composed primarily of elongated valve
leaflets, supported by chordae tendineae that insert into the
papillary muscles of the ventricular wall (Icardo et al., 1993;
Lamers et al., 1995; Lincoln et al., 2004). These valve
compartments consist of organized extracellular matrices with
proteoglycan characteristics of cartilage in the valve leaflets and
elastic features in the chordae tendineae (Icardo and Colvee,
1995; Lamers et al., 1995; Lincoln et al., 2004; Oosthoek et al.,
1998; Wessels et al., 1996). In mice, it has been demonstrated
that the diverse cell lineages that comprise these valve
compartments arise from a common population of progenitor⁎ Corresponding author. Fax: +1 513 636 5958.
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et al., 2004). The complex organization of the valve structures
reflects the contrasting demands of the opening and closing
motion of the valve leaflet and the tensile strength of the
supporting chordae tendineae. Little is known about how these
valvular compartments arise and become molecularly and
structurally diversified during development.
The first evidence of heart valve formation during embryo-
genesis is the formation of the endocardial cushions in the AV
canal and outflow tract. These cushions form as a result of
epithelial to mesenchymal transformation of the endocardial
endothelial cells induced by signals emanating from the
adjacent myocardium (Eisenberg and Markwald, 1995). In the
AV canal, the superior and inferior cushions then fuse to form
one central cushion with lateral cushions positioned on the left
and right parietal sides. The fused cushions mature into mitral
and tricuspid valve primordia that remodel and diversify into
functional valve structures, including leaflets and chordae
tendineae. In the chick, the developing valve leaflets express
chondroitin sulfate proteoglycans, including aggrecan and type
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cartilaginous structures (Chimal-Monroy et al., 2003; Holm-
dahl, 1986; Lincoln et al., 2004). In contrast, the supporting
chordae tendineae express the extracellular matrix (ECM)
protein tenascin and the bHLH transcription factor scleraxis,
which are characteristic of tendon cell lineages (Chiquet and
Fambrough, 1984; Lincoln et al., 2004; Schweitzer et al., 2001).
It is clear that the functional requirements of the developing
heart valves are very different from that of the limb buds and
somites, and yet, they share molecular and ECM characteristics.
In the developing limb buds and somites, the regulatory roles
of bone morphogenetic protein (BMP) and fibroblast growth
factor (FGF) signaling in cartilage and tendon cell lineage
determination and differentiation have been well characterized
(Brent and Tabin, 2002, 2004; Kardon, 1998; Tickle, 2002). In
the limb buds, BMP2 signaling induces expression of sox9 and
aggrecan in cartilage precursor cells (Yoon and Lyons, 2004).
In contrast, FGF, specifically FGF4, induces expression of
scleraxis and tenascin during tendon cell lineage differentiation
(Edom-Vovard and Duprez, 2004; Edom-Vovard et al., 2002;
Schweitzer et al., 2001). In the heart, BMP and FGF ligands are
differentially expressed in the AV canal and endocardial
cushions during valve development (Sugi et al., 2003; Yamada
et al., 1999) However, roles for these signaling pathways in
promoting cell lineage diversification during formation of the
valve leaflets and chordae tendineae have not previously been
examined.
We hypothesize that regulatory hierarchies that control
cartilage and tendon cell lineage differentiation in the limb
buds and somites function in diversification of valve precursor
cells during formation of heart valve leaflets and chordae
tendineae, respectively. In avian embryos, sox9 and aggrecan
are predominantly expressed in the valve leaflets, in contrast
to scleraxis and tenascin which are expressed in valve
supporting structures, including chordae tendineae. In cultured
valve precursor cells isolated from prefused endocardial
cushions, treatment with BMP2 results in increased expression
of sox9 and aggrecan, whereas FGF4 induces expression of
scleraxis and tenascin. The ability of BMP2 or FGF4 to
promote differentiation of diversified valve precursors cell
lineages is observed only in cells isolated from prefused
endocardial cushions. Once cushion fusion has occurred, the
valve progenitors cannot be redirected by BMP2 or FGF4
signaling and appear to have become determined to express
either aggrecan or tenascin. Together these analyses have
identified a striking similarity in molecular mechanisms
controlling cartilage- and tendon-like cell fate diversification
in valve precursor cells and in the developing limb buds and
somites.
Materials and methods
Chicken embryo collection
White leghorn chicken eggs (CBT Farms, MD) were incubated at 38°C
under high humidity, and embryos were collected at Hamburger Hamilton (HH)
stages 25 to 36, corresponding to embryonic (E) days 4.5 and 10 respectively
(Hamburger and Hamilton, 1951). For histology, hearts were dissected in 1×phosphate-buffered saline (PBS) and fixed for 2 h in 4% paraformaldehyde
(PFA)/PBS. After fixation, embryonic tissue was dehydrated in a graded
ethanol/PBS series (25%, 50%, 70%, 95%, 100%) and embedded in paraplast
(Sigma) for further processing. All animal procedures were approved and
performed in accordance with institutional guidelines.
In situ hybridization
The chicken aggrecan sequence (Genbank accession number NM_204955)
was amplified from HH stage 34 wing cDNA by reverse transcriptase
polymerase chain reaction (RT-PCR) using primers: forward 5′-CTGCGT-
TCCCTGAGATTAC-3′; and reverse, 5′-TTGCCAGGTCGATCTCAC-3′ and
confirmed by sequencing (Li et al., 1996). The 926-bp fragment was
subcloned into pGEM-T vector (Promega), and digoxigenin (DIG) UTP
labeled antisense riboprobe was synthesized with Sp6 polymerase from
plasmid linearized with NcoI. Antisense RNA probes were generated as
previously reported (Ehrman and Yutzey, 1999). Plasmids for generation of
chicken sox9 and scleraxis probes were kind gifts from Dr. J Chimal-Monroy
(Chimal-Monroy et al., 2003) and Dr. Edom-Vovard (Edom-Vovard et al.,
2002).
In situ hybridization (ISH) of sectioned tissue was carried out as previously
described (Somi et al., 2004) with the following modifications. HH stage 29 and
36 chicken hearts were paraffin embedded, and 16-μm-thick sections were
mounted onto Superfrost Plus microscope slides (Fisher Scientific). After
deparaffinization and hydration through a graded ethanol/distilled water series
(100%, 95%, 75%, 50%), slides were rinsed in 1×PBS. Tissue sections were
digested with 20 μg/ml proteinase K/PBS for 8 min at 37°C. Hybridizations
were carried out using Coverwell Incubation Chambers (Grace Biolabs) using
160 μl of 0.5 μg/ml DIG labeled riboprobe. After the color reaction (3–24 h),
slides were washed in 1×PBST (PBS/0.1% Tween 20) dehydrated in a graded
ethanol series, rinsed in xylene for 1 min and mounted with Cytoseal (Electron
Microscopy Sciences).
In some cases, ISH was performed on 14-μm frozen sections where hearts
were fixed in 4% PFA/PBS, infiltrated with graded sucrose/PBS (10%, 20%,
30%) solutions, and embedded in OCT (Electron Microscopy Scientific) (Stern,
1993). Cryostat sections were placed on superfrost slides, and ISH was carried
out with DIG labeled riboprobes as previously described (Toresson et al., 1999).
Color reactions were performed using BM Purple AP substrate (Roche) for 16–
72 h. Slides were washed in 1×PBS and allowed to air dry before being mounted
using Cytoseal.
Endocardial cushion cell culture
Dissociated cell culture
Embryonic chicken hearts were collected in 1×PBS at HH stages 25 and 29.
The AV canal was removed, and prefused (HH. stage 25) or fused (HH stage 29)
endocardial cushions were dissected away from the adjacent myocardial cell
layer using tungsten needles and collected in 50 μl media (10% Fetal Bovine
Serum (FBS), 1% chicken embryo extract (CEE) (Accurate Chemical, USA),
1% Penicillin/Streptomycin (P/S), 1 × M199 (Invitrogen)). Dissected cushions
were then treated with 100 μl 1 × trypsin–EDTA (Invitrogen) at 37°C for 5 min
and passed through a 25G1 1/2 needle 3 times. Dissociated AV cushion cells
derived from 12 chicken embryos were plated onto a 0.01% collagen-treated
two-well chamber slide (Labtek) and incubated for 4 days in the culture media.
200 ng/μl recombinant human (rh) BMP2, rhNoggin, rhFGF4 (R&D Systems)
or 20 μM SU5402 (Calbiochem) was added to the culture media at the time of
plating with full replenishment after 48 h. Cells were collected after 4 days of
culture for RNA isolation or fixed in 4% PFA/PBS for immunohistochemistry
(IHC). Alternatively for some IHC, cultured cells were fixed after 24 h of
culture.
Whole endocardial cushions cultured in matrigel
For examination of intact cushion development, HH stage 25 or 29 cushions
were placed individually between 2 × 15 μl of growth factor reduced Matrigel
(BD Biosciences) and cultured for 4 days in M199 supplemented with 1% CEE,
1% Insulin Transferrin Selenium (ITS) (Invitrogen), 1% P/S. Cultures were
visualized with an Olympus SZH10 microscope and images captured with
Olympus DP12 digital camera.
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For HH stage, 32 valve primordia cultures, AV canals were removed from
HH stage 32 embryonic chick hearts and using tungsten needles and the mitral
valve septal primordia were dissected away from the left septal side. Valve
primordia were then cultured on 13 mm, 0.1 μm Millipore filters floating in
supplemented M199 media (1% CEE, 1% ITS, 1% P/S). Treatments including
addition of 2.5 μl 200 ng/μl of BMP2, FGF4, or Noggin (or 20 μM SU5402)
were added directly to the surface of each primordium and replenished after 48
h. Following 3 days of culture, tissue from 4 filters (16 primordia) was collected
for RNA isolation or subjected to ISH or IHC as described below.
For bead implantation, whole endocardial cushions from HH stage 25
chicken embryos were dissected in 1×PBS and cultured on Millipore filters
floating in 1.5 ml media (1% CEE, 1% ITS, 1% P/S, M199 media).
Heparin-coated agarose beads (Sigma) soaked for 1 h on ice in 200 ng/μl
rhBMP2, rhNoggin, rhFGF4 or 0.1% bovine serum albumin (BSA) were
physically implanted into the HH stage 25 cushion tissue using fine forceps
that were then cultured for 3 days. Cushions cultured on filters were fixed
overnight in 4% PFA/PBS at 4°C and subjected to whole-mount ISH
(Wilkinson, 1993) for aggrecan, sox9, or scleraxis, with a modification of
15 min 20 μg/ml proteinase K/PBS treatment at room temperature.
Alternatively fixed cushions on filters were subjected to IHC for tenascin
expression (described below).
Immunohistochemistry
HH stage 29 and 36 embryonic chicken hearts were isolated and embedded
in paraplast as described above, and 5-μm sections were cut. Tissue sections or
bead-implanted cultures were subject to IHC. Mouse monoclonal antibody to
tenascin (M1B4) (Chiquet and Fambrough, 1984) was obtained from the
Developmental Studies Hybridoma Bank developed with the National Institute
of Child Health and Human Development (NICHD) and maintained by The
University of Iowa. For embryonic sections, antigen retrieval was carried out
by boiling sections on slides in 0.1 M glycine, pH 3.0 for 5 min, followed by
cooling at room temperature for 45 min. For cushions fixed on filters, the
glycine antigen retrieval step was substituted with treatment using 20 μg/ml
proteinase K/PBS for 15 min at 37°C. Following antigen retrieval, a
streptavidin/biotin and diamobenzidine (DAB) detection system (Pierce) was
used for colorimetric staining as recommended by the manufacturer's
instructions, with an additional 15% (in double distilled water) nuclear fast
red counterstain (Vectorlabs).
Dissociated cells from prefused endocardial cushions assessed for
expression of phosphorylated Smad 1/5/8 (pSmad1/5/8) and di-phosphorylated
ERK1/2 (dpERK1/2) were fixed in 4% PFA 24 h after treatment, washed twice
in 1×PBS, and treated with 3% hydrogen peroxide/PBS for 30 min.
Immunolabeling was performed using ABC peroxidase staining kit (Pierce)
according to the manufacturer's recommendations. Rabbit polyclonal antibodies
directed against pSmad 1/5/8 (Calbiochem) and dpERK1/2 (Biosource) were
used at 1:100 dilution in blocking solution (2% horse serum, 2% BSA, 0.1%NP-
40/PBS) and applied overnight at 4°C. Detection of antibody binding was
visualized using DAB substrate (Pierce) for 20 s to 1 min.
Dissociated cells from prefused and fused endocardial cushions for
fluorescent IHC double staining of aggrecan and tenascin were cultured for 4
days and then fixed in 4%PFA/PBS for 2 h and rinsed twice in 1×PBS. Fixed
cells were treated with 0.02 U/ml Chondroitinase ABC (Sigma)/50 mM Tris,
pH8.0, 60 mM sodium acetate, 0.02% BSA, for 30 min at 37°C, were washed
twice in 1×PBS and blocked (2% horse serum, 2%BSA, 0.1% NP-40/PBS) for
45 min. Tenascin antibody (M1B4) (1:200) was diluted in blocking solution, and
cells were incubated for 1 h. Cells were further washed 3 times in 0.1% NP-40/
1×PBS and consequently incubated with Alexa anti-mouse 488 secondary
antibody (1:200, 2 mg/ml, Molecular Probes) for 1 h. The blocking and antibody
application procedures were repeated using rabbit polyclonal anti-serum against
aggrecan (1:100, 400 μg/ml) (Chemicon) and respective Alexa anti-rabbit 568
antibody (1:200). Cells were finally washed and mounted in Vectorshield
(VectorLabs), viewed with an Olympus BX60 microscope, and captured using
Advanced SPOT image software.
Quantitation of the percentage of cells that express aggrecan or tenascin
apparent by immunofluorescence staining was calculated relative to the total
number of cells that express either cell lineage marker in each culture condition.Quantitation of the number of cells with nuclear pSmad1/5/8 reactivity or
cytoplasmic or nuclear expression of dpERK1/2 was determined relative to the
total number of cells. The average percentage of cells expressing aggrecan,
tenascin, pSmad1/5/8 or dpERK1/2 was determined from two independent
experiments for each culture condition, and stained cells were blindly counted
from 10 microscopic fields of each experimental run and the average recorded.
Statistical significance of observed differences were calculated using Student's t
test (P ≤ 0.05).
RT-PCR analysis of gene expression
RNAwas isolated from untreated or treated dissociated endocardial cushion
cells cultured in a 2-well plate (Labtek) using 200 μl Trizol reagent (Invitrogen).
Additionally RNA was similarly collected from 4 nylon filters containing 16
cultured cushions/primordia in total. cDNA was generated from isolated RNA
using SuperScript II (Invitrogen) following manufacturer's instructions. 1 μl
cDNA was subject to semi-quantitative RT-PCR or quantitative real-time RT-
PCR (MJ Research, Opticon 2) analysis using 20 pmol of the respective PCR
primers for aggrecan 5′-CCTGCCTGACCTCTTTGC-3′ and 5′-TGGGG-
AGGAGGGCAACAT-3′; sox9 5′-GGAAAGCGACGAGGACAAAT-3′ and
5′-TACTTGTAGTCGGGGTGGTC-3′ (Nonaka et al., 1999), tenascin 5′-
GCGAATTATCCGGCAGAAGC-3′ and 5′-TCTAATCTATTGCCTACATC-3′;
and scleraxis 5′-CGCGACCGCACCAACAGC-3′ and 5′-GTCCCCACAGCC-
CAGCCTCACG-3′. PCR reactions (95°C, 30 s; 55°C, 30 s; 72°C, 30 s; 35
cycles (aggrecan) or 95°C, 60 s; 59°C, 90 s; 72°C, 60 s; 35 cycles (sox9,
scleraxis, tenascin), included 0.1× Sybr Green (Molecular Probes) and
fluorescence was monitored at 72°C. Gene expression levels were quantified
based on the threshold cycle [C(t)] calibrated to a standard curve generated for
each primer pair, with HH stage 36 and 40 chicken wing cDNA and normalized
to GAPDH. RT-PCR results were compiled from at least four independent
experiments with reactions performed twice in duplicate. Real-time PCR data
shown are representative values of multiple (n = 3–6) experimental runs.
Results
ECM proteins and associated transcription factors are
differentially localized in AV valve leaflets and supporting
apparatus
Expression patterns of diversified cell lineage markers and
associated transcription factors characteristic of cartilage and
tendon cell types were examined in AV valve compartments of
chicken embryos in vivo using in situ hybridization (ISH) and
immunohistochemistry (IHC). In the limb buds, the cartilage
cell lineage is marked by the chondroitin sulfate proteoglycan,
aggrecan, which has been shown to be induced by the SRY
family transcription factor, sox9 (de Crombrugghe et al., 2000;
Sekiya et al., 2000). In contrast, tendon cells express the ECM
protein tenascin and the bHLH transcription factor scleraxis
(Chiquet and Fambrough, 1984; Edom-Vovard et al., 2002;
Schweitzer et al., 2001). The expression patterns of these genes
were analyzed in the embryonic chicken fused AV endocardial
cushions at HH stage 29 and in the maturing mitral valve at HH
stage 36 (Fig. 1).
The overlapping expression patterns of aggrecan and sox9
were examined during heart valve development (Fig. 1). At HH
stage 29, aggrecan expression is distinctly observed in the
primitive mural and septal tricuspid valve (tv) and septal mitral
valve (mv) primordia in the AV canal (Fig. 1A, arrowheads).
Expression is also apparent across the central cushion close to
the atrial septum, referred to as the atrial subseptal area (Fig. 1A,
arrow). In the HH stage 36 mitral valve, aggrecan expression is
Fig. 1. Genes associated with cartilage and tendon cell lineages are differentially
expressed during valve remodeling. In situ hybridization (A–D, G–H) and
immunohistochemistry (E–F) were used to examine patterns of aggrecan, sox9,
tenascin, and scleraxis expression in the avian triscupid (tv) and mitral valve
(mv) primordia at HH stage 29 (A, C, E, G) and in the mitral valve (mv) leaflets
at HH stage 36 (B, D, F, H). (A, C) Aggrecan and sox9 mRNA are similarly
expressed at HH stage 29 in the primitive tricuspid and mitral valve primordia
(arrowheads), and in the area (arrow) subjacent to the atrial septum (#). (B, D)
Aggrecan and sox9 expression at HH stage 36 is evident throughout the mitral
valve leaflets (arrows) and transseptal fibrous continuity (*) but not in the
chordae tendineae (arrowhead). (E, G) In contrast, tenascin and scleraxis are not
expressed in primitive tricuspid or mitral valve primordia at HH stage 29
(arrowheads), but they are expressed towards the core of the central endocardial
cushion (arrow). (F, H) Tenascin and scleraxis are expressed at HH stage 36 in
the chordae tendineae of the mv (arrowhead), with much reduced expression on
the atrial surface of the valve leaflets and tips (arrows). LA, left atrium, LV, left
ventricle, #, atrial septum, MV, mitral valve, TV, tricuspid valve.
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ventricular septum (Fig. 1B, *) and along the septal and parietal
mitral valve leaflets extending to the tips (Fig. 1B, arrows).
Expression was not detected in the supporting chordae
tendineae attached to the valve leaflet (Fig. 1B, arrowhead).
Like aggrecan, sox9 is expressed in the primitive mural and
septal tricuspid and mitral valve primordia (Fig. 1C, arrow-
heads) and in the atrial subseptal area of the central cushion
(Fig. 1C, arrow). By HH stage 36, sox9 is expressed in the
fibrous continuity (Fig. 1D, *) and throughout the mitral valve
leaflets extending to the tips (Fig. 1D, arrows). Sox9 expressionis not detected in the chordae tendineae (Fig. 1D, arrowhead).
Together, these analyses demonstrate that the cartilage-associ-
ated genes aggrecan and sox9 are colocalized during valve
remodeling in the primitive tricuspid and mitral valve primordia
and atrial subseptal area. At later stages, both are expressed in
the mitral valve leaflets but not in the chordae tendineae.
ISH and IHC were used to determine specific localization of
cells that express tenascin and scleraxis within the remodeling
AV valves (Figs. 1E–H). In contrast to aggrecan and sox9
expression, tenascin and scleraxis are not expressed in the
primitive tricuspid or mitral valve primordia (Figs. 1E, G,
arrowheads) but are expressed towards the subseptal core of the
central cushion (Figs. 1E, G, arrow). At HH stage 36, tenascin is
present in the transseptal fibrous continuity (Fig. 1F, *) and
throughout the chordae tendineae (Fig. 1F, arrowhead).
Expression is not observed along the atrial surface of the
valve leaflet or at the leaflet tips (Fig. 1F, arrows). Consistent
with tenascin localization, scleraxis is expressed in the
transseptal fibrous continuity (data not shown), in the
ventricular surface of the leaflets (Fig. 1H, right arrowhead),
and throughout the chordae tendineae (Fig. 1H, left arrowhead),
but is undetectable at the distal tips of the mitral valve leaflets
(Fig. 1H, arrows). The striking differential localization of cells
that express aggrecan and sox9 versus tenascin and scleraxis
during valvulogenesis appears to reflect distinct diversified cell
types in the valve leaflet and chordae tendineae compartments.
Cultured valve precursor cells from fused, but not prefused,
endocardial cushions express tenascin and exhibit advanced
morphogenesis
Expression of aggrecan or tenascin is undetectable in AV
endocardial cushions prior to fusion at HH stage 25 (data not
shown) but is apparent after cushion fusion at HH stage 29 (Fig.
1). The relative potential of prefused (HH stage 25) (Fig. 2A)
and fused (HH stage 29) (Fig. 2D) endocardial cushion cells to
associate and express ECM proteins was assessed in dissociated
(Figs. 2B, E) and whole cushion culture systems (Figs. 2C, F).
In each culture system, the myocardium is removed from
dissected endocardial cushions to eliminate inductive signals
emanating from this cell layer. Cells in the dissociated cultures
are placed directly on collagen-coated tissue culture dishes at
low density to minimize intercellular interactions (Figs. 2B, E).
In contrast, whole cushion cultures surrounded by matrigel,
maintain their cell–cell contacts, and allow outgrowths of the
cushion cells and ECM in 3 dimensions (3D) (Figs. 2C, F). Both
systems were used to evaluate changes in ECM deposition and
cell association from prefused or fused endocardial cushion
cells. Cells cultured in the dissociated system were subjected to
IHC for tenascin as an indicator of ECM deposition (Figs. 2B,
E). Cells from prefused endocardial cushion cells remain
mesenchymal in morphology (Fig. 2B, arrow) in contrast to
cells from fused endocardial cushions that form complex
networks of associated cells that express tenascin (Fig. 2E,
arrows). Similarly, aggregates of extended processes, sugges-
tive of advanced morphogenesis, are seen in fused, but not
prefused, endocardial cushions cultured in 2D or 3D cultures
Fig. 2. Fused endocardial cushions are more advanced in ECM deposition and morphogenesis compared to prefused cushions. The potential of prefused (HH stage 25)
(A) and fused (HH stage 29) (D) endocardial cushion (EC) cells to associate and express ECM proteins was examined in flat dissociated (B, E) and whole matrigel (C,
F) cushion culture systems. (B, E) Cells from prefused and fused endocardial cushions were cultured with minimal cell–cell contact and subjected to
immunohistochemistry for tenascin. (B) Cells from prefused endocardial cushions remain mesenchymal in morphology (arrow) in contrast to cells from fused cushions
(E) that show an increase in tenascin expression and advanced morphogenesis (arrow). (C) In a 3D matrigel system, whole prefused cushions do not show cellular
associations (arrow), compared to fused whole cushion tissue (F) (arrow). EC, endocardial cushion, V, ventricle.
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prefused cushions are relatively unable to express ECM proteins
and undergo aggregation, compared to fused endocardial
cushion cells that are more advanced in their morphology.
Therefore, cushion fusion appears to represent an important
developmental event in the determination and differentiation
potential of valve progenitor cells.
BMP2 or FGF4 treatment induces diversification of cultured
valve progenitor cells from prefused, but not fused, endocardial
cushions
BMP2 and FGF4 have previously been shown to regulate
cartilage and tendon cell fates respectively in the developing
limb buds and somites, and these growth factors are expressed
in the AV canal during heart development (Sugi et al., 2003;
Yamada et al., 1999). The ability of exogenous BMP2 or FGF4
treatment to promote expression of genes characteristic of
cartilage or tendon cell lineages in cultured valve precursor cells
was examined. The obvious difference in cell morphology and
ECM protein expression between prefused and fused endocar-
dial cushions (Fig. 2) prompted examination of valve cell
lineage diversification at both time points. Cells from prefused
(HH stage 25) or fused (HH stage 29) endocardial cushions
were subjected to no treatment or treatment with BMP2, a BMP
antagonist Noggin, FGF4, or a specific FGF receptor inhibitor
SU5402. Following treatment, expression of aggrecan, associ-
ated with cartilage cell types, and tenascin, expressed in
tendons, was examined in single cells using fluorescent double
staining IHC (Figs. 3A–J) and quantified in the progenitor
population as a percentage of the total number of cells
expressing either cell lineage marker (Fig. 3K).In prefused cushion cell cultures, BMP2 treatment is
sufficient to induce aggrecan protein expression apparent by
IHC in individual cells (Fig. 3B) compared to untreated controls
(Fig. 3A). An increase in the percentage of cells expressing
aggrecan is also seen following inhibition of the FGF pathway
using SU5402 (Fig. 3E). In contrast, FGF4 treatment, or
inhibition of the BMP pathway by Noggin treatment, increases
the percentage of cells expressing tenascin (Fig. 3H). Merged
images of aggrecan and tenascin expression following each
treatment show no overlap of expression at the single cell level
(data not shown). These regulatory relationships for aggrecan
and tenascin expression are consistent with BMP promotion of
chondrogenesis and FGF regulation of tendon development,
respectively, in other embryonic progenitor cell populations
(Brent and Tabin, 2002; Yoon and Lyons, 2004).
The number of cells expressing aggrecan or tenascin in
populations of BMP2, Noggin, FGF4, or SU5402 treated cells
from prefused or fused endocardial cushions was quantitated
and compared to untreated controls. Cells immunopositive for
either aggrecan or tenascin were counted in 20 microscopic
fields from two independent experiments and recorded as a
percentage of the total number of immunopositive cells (Fig.
3K). The percentage of cells in cultures from prefused
endocardial cushions expressing aggrecan increased by 20–
30% following treatment with BMP2, or the FGF inhibitor,
SU5402. This was accompanied by a comparative 20–30% loss
in tenascin expression. Similarly, the approximate 40–50%
increase in tenascin expression following FGF4 or Noggin
treatment is associated with a 40–50% loss of aggrecan
expression. In untreated cells, the percentage of cells immuno-
positive for aggrecan or tenascin was approximately equal. The
significant changes in aggrecan and tenascin expression in
Fig. 3. Aggrecan and tenascin are differentially expressed in cells from prefused cultures depending on BMP2 or FGF4 signaling status. Aggrecan (A–E) and tenascin
(F–J) protein expression was examined in cultured dissociated cells from prefused cushions following exposure to BMP2 (B, G), Noggin (C, H), FGF4 (D, I) or
SU5402 (E, J) treatment. Double staining immunohistochemistry shows expression of aggrecan (red) and tenascin (green) in the same microscopic field. Expression of
aggrecan was apparent when cells were treated with BMP2 (B) or SU5402 (E) compared to untreated controls (A). Tenascin expression was increased following
treatment with Noggin (H) or FGF4 (I). On a single cell level, arrows and arrowheads show the same single cell being positive for either aggrecan (arrows) or tenascin
(arrowheads), and no cells were observed to express both proteins. The percentage of immunopositive cells from prefused or fused endocardial cushions that express
aggrecan (white) or tenascin (black) following either no treatment or treatment with BMP2, Noggin, FGF4, or SU5402 was quantified (K). Statistical significance of
the percentage of cells expressing aggrecan (*) or tenascin (#) was determined compared to untreated controls using Student's t test (P b 0.01).
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significant change in the expression of these markers following
BMP2, FGF4, Noggin, or SU5402 treatment in cells from fused
cushions. These data are consistent with a bipotent valve
progenitor cell population present in prefused endocardial
cushions that become less plastic once the endocardial cushions
have fused.
The ability of BMP2 and FGF4 regulatory pathways to
promote heart valve lineage diversification in cells from
prefused (Figs. 4A, B) or fused (Fig. 4C) endocardial cushions
was further examined at the gene expression level. Expression
levels of aggrecan, sox9, scleraxis, and tenascin were
determined using semi-quantitative and real-time PCR follow-
ing BMP2, Noggin, FGF4, or SU5402 treatment. Effects of
BMP2 or FGF4 treatment on cell lineage differentiation at laterstages of remodeling were examined in whole mitral valve
septal primordium (HH stage 32) cultured on floating nylon
membranes (Fig. 4C). By semi-quantitative RT-PCR, increased
aggrecan and sox9 expression was observed in cultured cells
from prefused cushions treated with BMP2, while increased
scleraxis and tenascin expression was seen following FGF4 or
Noggin treatment. Changes in gene expression levels in treated
or untreated cells were further quantified by real-time RT-PCR.
In these analyses, BMP2 treatment increased sox9 (31-fold)
and aggrecan (62-fold) expression compared to untreated
controls. Expression of sox9 and aggrecan was also increased
following SU5402 treatment to inhibit FGF signaling (Fig.
4B). No significant increase in scleraxis or tenascin expression
was seen with BMP2 or SU5402 treatments. However, FGF4
treatment induced expression of tenascin (21-fold) and
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Fig. 5. BMP2 or SU5402 treatment of valve precursor cells increases Smad1/5/8 phosphorylation, while treatment with FGF4 or Noggin increases dpERK1/2
reactivity. Expression of pSmad1/5/8, a downstream effector molecule of BMP signaling, and dpERK1/2 indicative of FGF signaling activity were examined following
growth factor treatment of prefused (HH stage 25) valve precursor cells. The percentage of cells expressing nuclear pSmad1/5/8 is significantly increased following
treatment with BMP2 or SU5402 compared to untreated cells. This increase is expression is not seen following treatment with FGF4 or Noggin. Conversely, FGF4 or
Noggin treatment is associated with a significant increase in nuclear and cytoplasmic expression of dpERK compared to untreated cells or cells treated with BMP2 or
SU5402. Statistical significance is determined using Student's t test (P b 0.05) compared to untreated controls (pSmad 1/5/8 (*), dpERK1/2 (#)).
297J. Lincoln et al. / Developmental Biology 292 (2006) 290–302scleraxis (7-fold) over untreated control, without altering sox9
or aggrecan expression. Inhibition of BMP signaling with
Noggin does not affect aggrecan or sox9 expression but does
induce tenascin (44-fold) scleraxis (3-fold) expression (Fig.
4B).
In contrast to changes in gene expression of treated cells
from prefused endocardial cushions, cultured cells from fused
cushions (HH stage 29) or valve primordia (HH stage 32) did
not exhibit significant changes in expression levels of aggrecan
or tenascin following BMP2 or FGF4 treatment compared to
untreated controls (Fig. 4C). This finding is consistent with the
observation that cells from fused endocardial cushions do not
alter expression of aggrecan or tenascin when BMP or FGF
signaling is altered. This is in contrast to cells from prefused
endocardial cushions that can be induced to express either
cartilage or tendon cell markers by BMP2 or FGF4 signaling
respectively.
The downstream signaling mediators activated following
BMP2 and FGF4 treatment were examined in prefused
dissociated cushion cells (HH stage 25) using IHC for
pSmad1/5/8 and dpERK1/2. Phosphorylation and nuclear
localization of Smad1/5/8 occur with BMP signaling, whereas
MAPK/ERK1/2 is phosphorylated as a result of FGF pathwayFig. 4. BMP2 or SU5402 treatment induces aggrecan and sox9 gene expression, wh
cells from prefused, but not fused, endocardial cushions. Semi-quantitative and qu
scleraxis expression in cells from prefused (A, B) or fused (C) endocardial cushion
aggrecan, sox9, tenascin, and scleraxis expression are shown normalized to GAP
representative experiments of at least three independent samples. Standard error bars w
of representative data.activation (Corson et al., 2003; Faure et al., 2000; Payne et al.,
1991). Changes in pSmad1/5/8 or dpERK1/2 expression
following each treatment is shown in Fig. 5 as a percentage of
the total number of cells cultured in each condition. Following
BMP2 treatment, there is a significant increase in pSmad1/5/
8 reactivity compared to untreated controls. This activation of
pSmad1/5/8 expression is not observed when cells are treated
with the BMP antagonist Noggin or with FGF4 (Fig. 5).
Interestingly, in the absence of added BMP ligand, the
inhibition of FGF signaling by SU5402 treatment also increases
pSmad1/5/8 activity over untreated controls. In addition, FGF4
treatment significantly increases dpERK1/2 reactivity by 27%
compared to untreated cells, as does the BMP antagonist
Noggin (12% increase). The significant increase in phosphor-
ylation of ERK1/2 following FGF4 or Noggin treatment is not
observed in BMP2 or SU5402 treated cells (Fig. 5). These
changes in phosphorylation of intracellular signaling effectors
support a mechanism whereby BMP2 signaling mediated by
Smad1/5/8 activates sox9 and aggrecan expression, and FGF
acting through dpERK promotes scleraxis and tenascin
expression in prefused valve precursor cells. In addition,
inhibition of BMP results in increased ERK1/2 phosphoryla-
tion, and antagonism of FGF signaling results in increasedile FGF4 or Noggin treatment increases expression of tenascin and scleraxis in
antitative real-time PCR was used to examine aggrecan, sox9, tenascin, and
s treated with BMP2, Noggin, FGF4, or SU5402. Real-time RT-PCR levels of
DH as a fold change relative to untreated cells (B, C). Data shown are from
ere generated from the standard error of the mean from reactions run in duplicate
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antagonistic relationship between BMP and FGF signaling
pathways.
Local application of BMP2 or FGF4 to prefused endocardial
cushions induces expression of genes characteristic of
cartilage and tendon cell lineages
Cultured cells from prefused endocardial cushions are unable
to diversify into cartilage- or tendon-like cell phenotypes
without the addition of BMP2 or FGF4 (Figs. 3, 4). The ability
of localized BMP2, Noggin, and FGF4 treatment to induce
expression of sox9, aggrecan, scleraxis, and tenascin in intact
prefused endocardial cushions was examined. Whole cushion
cultures maintain cell organization and signaling interactions
with adjacent mesenchymal cells, ECM, and the overlying
endocardium. The implantation of BMP2, Noggin, or FGF4
treated agarose beads in whole prefused cushions was used toFig. 6. Implantation of BMP2 treated beads in intact prefused cushions induces expre
expression of tenascin and scleraxis. BSA, BMP2, Noggin, or FGF4 infused agarose
membranes floating in media. Expression of aggrecan (A–D), sox9 (E–H), and scle
detected by immunohistochemistry (I–L). Expression of aggrecan (B) and sox9 (F) w
not seen following implantation of BSA (A, E), Noggin (C, G), or FGF4 (D, H)
implantation of Noggin (K, O) and FGF4 (L, P) compared to BSA (I, M), or BMP2determine the effects of localized ectopic signaling on cell
lineage differentiation when cell–cell and cell–matrix interac-
tions are maintained. Induction of aggrecan, sox9, and scleraxis
expression in treated cushions was examined by ISH, while
tenascin expression was detected using IHC (Fig. 6).
In prefused cushions implantation of BMP2 treated beads
resulted in increased expression of aggrecan and sox9 (Figs.
6B, F, arrow), but changes in scleraxis or tenascin (Figs. 6J, N)
expression were not observed compared to BSA treated controls
(Figs. 6A, E, I, M). However, FGF4 bead implantation was
sufficient to induce tenascin and scleraxis (Figs. 6L, P, arrow)
but not aggrecan or sox9 expression (Figs. 6D, H). In cells from
prefused endocardial cushions, Noggin, like FGF4, induced
tenascin expression surrounding the implanted bead (Fig. 6K)
with a small increase in scleraxis expression (Fig. 6O, arrow).
No increase in aggrecan or sox9 expression was observed
following Noggin bead implantation (Figs. 6C, G). In contrast
to prefused cushions, implantation of BMP2, FGF4, or Nogginssion of aggrecan and sox9, while FGF4 or Noggin bead implantation increases
beads were implanted on whole prefused endocardial cushions cultured on nylon
raxis (M–P) was detected by in situ hybridization, and tenascin expression was
as observed proximal to the BMP2 implanted bead (arrow). This induction was
beads. Tenascin and scleraxis expression (arrow) was induced with localized
(J, N) treated cultures.
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not alter expression of cartilage and tendon markers (data not
shown). These observations are consistent with the inability of
fused endocardial cushion cells to alter differentiated cell
phenotypes when exposed to altered BMP or FGF signaling.
Together, these data demonstrate that local application of BMP2
or FGF4 are sufficient to promote diversified valve cell
phenotypes within the context of intact prefused endocardial
cushions.
Discussion
During heart development, the AV valve leaflets and chordae
tendineae express transcription factors and ECM proteins
associated with cartilage and tendon cell lineages (Lincoln et
al., 2004). In mice, cell fate analysis demonstrated that these
diversified cell lineages arise through differentiation of valve
progenitor cells present in the endocardial cushions (de Lange et
al., 2004; Lincoln et al., 2004). In this study, detailed in vitro
analyses of valve progenitor cells derived from avian prefused
endocardial cushions demonstrate that BMP2 treatment or
inhibition of FGF signaling induces expression of sox9 and
aggrecan as well as phosphorylation of Smad1/5/8. In contrast,
FGF4 treatment or inhibition of BMP signaling promotes
expression of scleraxis and tenascin in association with
activated dpERK1/2. The inductive or repressive effects of
BMP2 or FGF4 signaling status on expression of distinct ECM
proteins are consistent with a cell lineage ‘switch’ in bipotent
valve precursor cells. The BMP2 and FGF4 pathways that
promote valve precursor cell diversification in vitro have also
been reported to regulate cartilage and tendon cell lineage
development in the developing limb buds and somites in vivo
(Chimal-Monroy et al., 2003; Edom-Vovard et al., 2002;
Schweitzer et al., 2001; Yoon and Lyons, 2004). The diversified
cell lineage potential of endocardial cushion cells changes
during cushion fusion, as indicated by the plasticity of cells
from prefused, but not fused, cushions. These observations are
consistent with a cell lineage determination event regulated by
the proximity of BMP or FGF signaling during cushion fusion
that establishes diversified cell types of the valve leaflets and
chordae tendineae with molecular characteristics of cartilage
and tendons, respectively.
Compartmentalization and cell lineage differentiation of heart
valve structures
The valve leaflet and chordae tendineae compartments have
been defined structurally in mature valves based on restricted
expression of transcription factors and ECM proteins, several of
which are also expressed in developing cartilage and tendon cell
types (Lincoln et al., 2004). The presence of aggrecan and sox9
expression in the valve leaflets and scleraxis and tenascin in the
chordae tendineae is evidence for the diversification of valve
precursor cells into diversified cell lineages that occupy distinct
compartments of the valve structures. The structural diversifi-
cation of ECM in the valve leaflets and chordae tendineae is
likely to be important for AV valve function throughout life(Schoen, 1997). Unidirectional blood flow through the heart
requires regulated opening and closing of strong, but flexible,
valve leaflets in the AV canal, associated with changes in
tension of the chordae tendineae. The proteoglycan component
of the valve leaflets resists compression but allows flexibility of
motion during the cardiac cycle, while the ‘elastic’ chordae
tendineae support the leaflets with tensile strength (Schoen,
1997). Therefore, the diversification of the endocardial cushion
cells into these distinct valve compartments is integral to the
structure and function of the normal AV valves (de Lange et al.,
2004; Lamers et al., 1995; Lincoln et al., 2004; Oosthoek et al.,
1998; Wessels et al., 1996).
Differences in diversified cell lineage potential of valve
progenitors from prefused and fused endocardial cushions have
emerged from this study. Increased BMP2 or loss of FGF
signaling induces expression of aggrecan and sox9, and
increased FGF4 or loss of BMP signaling is sufficient to
induce tenascin and scleraxis in cultured valve progenitors from
isolated prefused, but not fused, endocardial cushions. Prior to
fusion, expression of either aggrecan or tenascin is not observed
in vivo, however, both are detected following fusion. Likewise
in vitro, untreated cells from prefused endocardial cushions do
not express tenascin or display cellular aggregations, in contrast
to cells from fused cushions that are more advanced in ECM
deposition and morphology. The plasticity in cell lineage
potential of cells from prefused cushions is evident following
BMP2 or FGF4 treatments that promote expression of
diversified ECM genes. However, this cell lineage plasticity is
lost in cells from fused cushions that no longer alter expression
of aggrecan or tenascin depending on BMP or FGF signaling
status. Therefore, endocardial cushion fusion appears to be an
important developmental event associated with restricted
lineage potential of valve precursor cells.
BMP and FGF regulation of cartilage and tendon cell lineage
development
The regulation of cartilage and tendon cell lineage diversi-
fication has been characterized during limb bud and somite
development, and these same pathways appear to be important
for cell lineage diversification during formation of heart valve
structures (Kardon, 1998; Martin, 1998; Tickle, 2002). In the
limb bud mesenchyme, BMP2 induces sox9 and aggrecan
expression, required for early stages of cartilage cell lineage
commitment (Yoon and Lyons, 2004). In the somites, FGF4 is
associated with increased dpERK1/2 and promotes and main-
tains expression of scleraxis and tenascin during development of
tendon progenitor cells (Brent and Tabin, 2004; Edom-Vovard et
al., 2002; Smith et al., 2005). Noggin, when ectopically
expressed in developing cartilage, is sufficient to inhibit BMP-
induced expression of cartilage lineage genes and to promote
expression of scleraxis, associated with tendon development
(Brunet et al., 1998; Capdevila and Johnson, 1998; Merino et al.,
1998; Pizette and Niswander, 2000; Schweitzer et al., 2001).
Together, these studies have defined an antagonistic relationship
between BMP and FGF signaling pathways that controls
cartilage versus tendon cell determination in common progenitor
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provide evidence for a similar relationship between BMP and
FGF signaling pathways, including downstream mediators, in
the control of AV valve progenitor cell lineage diversification.
BMP2 and FGF4 signaling pathways and heart valve
development
BMP and FGF signaling pathways have previously been
shown to be important for normal heart development, in
particular for endocardial cushion formation (Delot, 2003;
Galvin et al., 2000; Gaussin et al., 2002; Jiao et al., 2003; Ma et
al., 2005; Sugi et al., 2003, 2004). Previous studies have
demonstrated that BMP2 is expressed in the AV canal
myocardium adjacent to the endocardial cushions during fusion,
while protein levels of BMP2 and activated effector molecules
pSmad1/5/8 are detectable throughout the cushion mesen-
chyme. Therefore, BMP2 signaling is active during cushion
fusion when valve precursor cells become diversified (Brent
and Tabin, 2002; Keyes et al., 2003; Ma et al., 2005; Somi et al.,
2004; Yamada et al., 1999). A role for BMP signaling during
cushion formation is supported by recent work identifying early
roles for BMP2, -4, and a BMP receptor gene, ALK3 during
EMT and formation of the AVendocardial cushions (Gaussin et
al., 2002; Jiao et al., 2003; Ma et al., 2005; Sugi et al., 2004). A
later role for BMP signaling during heart valve remodeling and
maturation has been identified in mice with a conditional loss of
Smad6, a downstream BMP inhibitor, that exhibit hyperplastic
cushions that fail to remodel into valves (Galvin et al., 2000;
Yamada et al., 1999). Collectively, this study and others have
identified roles for BMP2 signaling through phosphorylation of
Smad1/5/8 during atrioventricular valve development, however,
further work is required to confirm the in vivo regulation of cell
lineage diversification of valve progenitor cells by BMP2
signaling.
Less is known about the roles of FGF signaling during heart
valve development. Several FGF ligands and downstream
signaling molecules including dpERK1/2 are expressed in the
heart during cushion formation (Karabagli et al., 2002; Lavine
et al., 2005; Liberatore and Yutzey, 2004). In particular, FGF4 is
expressed in the cushion mesenchyme and surrounding
myocardium associated with dpERK expression in the chick.
These expression patterns support the importance of FGF
signaling in regulating gene expression of tendon-associated
genes during cell lineage diversification, consistent with the
FGF and dpERK activation of scleraxis in the developing
somites. (Brent and Tabin, 2004; Smith et al., 2005; Sugi et al.,
2003). The significant activation of dpERK1/2 in response to
FGF4 treatment (or inhibition of BMP signaling), along with
previously described expression patterns of the growth factor
and downstream mediators during valvulogenesis, strongly
suggest that FGF signaling through ERK1/2 phosphorylation
regulates expression of scleraxis and tenascin during diversi-
fication of valve precursor cells.
The balance of BMP2 and FGF4 signaling appears to be
important in regulating diversification of multipotential valve
precursor cells. The promotion of diversified cell phenotypes byBMP2 and FGF4 signaling is associated with increased
activation of intracellular mediators pSmad1/5/8 and
dpERK1/2, respectively. In addition antagonism of BMP
signaling by Noggin results in increased ERK1/2 phosphory-
lation, while FGF inhibition increases phosphorylation of
Smad1/5/8. These results are consistent with an antagonistic
relationship of BMP and FGF pathways at the level of
intracellular signaling intermediates. A similar relationship
has been observed in Xenopus embryos, where activated ERK1/
2 can directly phosphorylate the linker region of Smad1
resulting in attenuated nuclear activity (Kretzschmar et al.,
1997; Massague, 2003). Therefore, diversification of cell
lineages from bipotent valve precursor cells appears to be
regulated by an antagonistic relationship between BMP and
FGF signaling pathways that extends to the level of intracellular
effector proteins.
Heart valve cell lineage development and congenital heart
disease
The majority of congenital heart defects are due to
abnormalities in the formation of valvuloseptal structures
(Hoffman and Kaplan, 2002). Malformations in the mitral or
tricuspid valve leaflets and/or chordae tendineae can result in
regurgitation or stenosis, and these valve lesions are often
associated with an imbalance in ECM deposition or degradation,
resulting in floppy or stiffened dysfunctional valves (Bender,
1992; Davies et al., 1978; Rabkin et al., 2001; Schoen, 1997;
Tamura et al., 1995). For example, myxomatous valves,
observed in predominantly older patients, are characterized by
a distinct loss of ECM organization indicated by increased
ectopic staining for proteoglycans and a decrease in elastic
matrix associated with cartilage and tendon cell lineages (Rabkin
et al., 2001). The pathogenesis of valve ECM abnormalities in
both congenital and later acquired valve disease is uncertain, and
it remains unclear if the ECM abnormalities are a result of
aberrant molecular signaling during embryonic valve develop-
ment or if matrix organization deteriorates in response to valve
malfunction. This study has shown, using multiple assays, that
valve precursor cells in the endocardial cushions give rise to
diversified cells with ECM profiles characteristic of cartilage
and tendons. It remains to be determined if ECM disorganization
observed in valve disease could be associated with regulation by
BMP and FGF signaling pathways as a compensatory
mechanism that results in abnormal distribution of ECM
proteins, leading to valve dysfunction.
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